Home › VivaMab And ADC Therapeutics Announce Antibody Licensing Deal For Novel ADC Candidate To Target Hematologic Cancers
 

Keywords :   


VivaMab And ADC Therapeutics Announce Antibody Licensing Deal For Novel ADC Candidate To Target Hematologic Cancers

2013-06-24 09:13:00| drugdiscoveryonline News Articles

VivaMab, a therapeutic development division of BioAtla LLC, and ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates ('ADCs'), recently announced a licensing deal for a novel antibody against an undisclosed hematological cancer target

Tags: deal target candidate licensing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11NI rise hits workers harder than employers, says OBR
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 8
05.11Tropical Storm Rafael Public Advisory Number 8
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 8
05.11Lenzing Expands Nonwovens Range
05.11Netflix Europe offices raided in tax fraud probe
More »